Market Cap | 145.21M | P/E | - | EPS this Y | 4.50% | Ern Qtrly Grth | - |
Income | -39.33M | Forward P/E | 2.23 | EPS next Y | 157.10% | 50D Avg Chg | -23.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -23.00% |
Dividend | N/A | Price/Book | 1.47 | EPS next 5Y | - | 52W High Chg | -47.00% |
Recommedations | 2.00 | Quick Ratio | 3.65 | Shares Outstanding | 159.10M | 52W Low Chg | 19.00% |
Insider Own | 7.74% | ROA | -23.21% | Shares Float | 146.77M | Beta | 1.44 |
Inst Own | 17.03% | ROE | -40.97% | Shares Shorted/Prior | 12.18M/11.58M | Price | 0.91 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 2,028,708 | Target Price | - |
Oper. Margin | - | Earnings Date | May 10 | Volume | 1,696,404 | Change | -4.26% |
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
HC Wainwright & Co. | Buy | Feb 14, 24 |
HC Wainwright & Co. | Buy | Aug 10, 23 |
HC Wainwright & Co. | Buy | Aug 1, 23 |
HC Wainwright & Co. | Buy | May 30, 23 |
HC Wainwright & Co. | Buy | Apr 3, 23 |
HC Wainwright & Co. | Buy | Mar 29, 23 |
HC Wainwright & Co. | Buy | Jan 18, 22 |
Maxim Group | Buy | Nov 30, 21 |
HC Wainwright & Co. | Buy | May 23, 18 |